Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 170
- Registration Number
- NCT00354341
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT00353522
A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
Phase 1
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT00353262
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 415
- Registration Number
- NCT00353418
A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Phase 3
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT00349336
A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 27
- Registration Number
- NCT00337649
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT00337701
Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.
Phase 4
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2012-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 155
- Registration Number
- NCT00337493
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 736
- Registration Number
- NCT00333775
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Phase 2
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT00327535
© Copyright 2025. All Rights Reserved by MedPath